Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Clinical trial NCT04061512 · RECRUITING

Trial details

NCT number: NCT04061512
Sponsor: University College, London
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Waldenstrom Macroglobulinemia

Start date: 2020-02-03
Primary completion: 2030-03-01
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.